Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Long-Term Risk of Immune-Related diseases.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
24 Mar 2023
24 Mar 2023
Historique:
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive enzymatic disorder, particularly prevalent in Africa, Asia and the Middle East. In the US, about 14% of black men are affected. Individuals with G6PD deficiency are often asymptomatic but may develop hemolysis following an infection or upon consumption of specific medications. Despite some evidence that G6PD deficiency affects the immune system, the long- term health risks associated with G6PD deficiency had not been studied in a large population. In this retrospective cohort study, health records from G6PD deficient individuals were compared to matched controls in a national healthcare provider in Israel (Leumit Health Services). Rates of infectious diseases, allergic conditions and autoimmune disorders were compared between groups. The cohort included 7,473 G6PD deficient subjects (68.7% men) matched with 29,892 control subjects (4:1 ratio) of the same age, gender, socioeconomic status and ethnic group, followed during 14.3±6.2 years.Significantly increased rates for autoimmune disorders, infectious diseases and allergic conditions were observed throughout this period. Notable increases were observed for rheumatoid arthritis (OR 2.41, p<0.001), systemic lupus erythematosus (OR 4.56, p<0.001), scleroderma (OR 6.87, p<0.001), pernicious anemia (OR=18.70, P<0.001), fibromyalgia (OR 1.98, p<0.001), Graves' disease (OR 1.46, P=0.001), and Hashimoto's thyroiditis (OR 1.26, P=0.001). These findings were corroborated with elevated rates of positive autoimmune serology and higher rates of treatment with medications commonly used to treat autoimmune conditions in the G6PD deficient group. G6PD deficient individuals suffer from higher rates of autoimmune disorders, infectious diseases, and allergic conditions.
Sections du résumé
BACKGROUND
BACKGROUND
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive enzymatic disorder, particularly prevalent in Africa, Asia and the Middle East. In the US, about 14% of black men are affected. Individuals with G6PD deficiency are often asymptomatic but may develop hemolysis following an infection or upon consumption of specific medications. Despite some evidence that G6PD deficiency affects the immune system, the long- term health risks associated with G6PD deficiency had not been studied in a large population.
METHODS
METHODS
In this retrospective cohort study, health records from G6PD deficient individuals were compared to matched controls in a national healthcare provider in Israel (Leumit Health Services). Rates of infectious diseases, allergic conditions and autoimmune disorders were compared between groups.
RESULTS
RESULTS
The cohort included 7,473 G6PD deficient subjects (68.7% men) matched with 29,892 control subjects (4:1 ratio) of the same age, gender, socioeconomic status and ethnic group, followed during 14.3±6.2 years.Significantly increased rates for autoimmune disorders, infectious diseases and allergic conditions were observed throughout this period. Notable increases were observed for rheumatoid arthritis (OR 2.41, p<0.001), systemic lupus erythematosus (OR 4.56, p<0.001), scleroderma (OR 6.87, p<0.001), pernicious anemia (OR=18.70, P<0.001), fibromyalgia (OR 1.98, p<0.001), Graves' disease (OR 1.46, P=0.001), and Hashimoto's thyroiditis (OR 1.26, P=0.001). These findings were corroborated with elevated rates of positive autoimmune serology and higher rates of treatment with medications commonly used to treat autoimmune conditions in the G6PD deficient group.
CONCLUSION
CONCLUSIONS
G6PD deficient individuals suffer from higher rates of autoimmune disorders, infectious diseases, and allergic conditions.
Identifiants
pubmed: 37090544
doi: 10.1101/2023.03.23.23287616
pmc: PMC10120794
pii:
doi:
Types de publication
Preprint
Langues
eng
Commentaires et corrections
Type : UpdateIn
Références
Blood. 1998 Jan 15;91(2):706-9
pubmed: 9427729
J Med Life. 2016 Jan-Mar;9(1):34-38
pubmed: 27974910
Microbes Infect. 2011 Feb;13(2):109-20
pubmed: 20971207
Physiol Rev. 2019 Apr 1;99(2):1281-1324
pubmed: 30864875
Blood. 2003 Jun 15;101(12):5033-8
pubmed: 12586629
Front Immunol. 2021 Jul 14;12:694928
pubmed: 34335607
ISRN Allergy. 2011 Apr 19;2011:832560
pubmed: 23724233
BMJ. 2021 Nov 24;375:e067873
pubmed: 34819275
Free Radic Biol Med. 2005 Mar 15;38(6):719-28
pubmed: 15721982
Blood. 2002 Aug 1;100(3):1026-30
pubmed: 12130518
Blood. 1994 Dec 1;84(11):3613-36
pubmed: 7949118
Future Microbiol. 2022 Sep;17:1161-1170
pubmed: 35880537
Nature. 1995 Jul 20;376(6537):246-9
pubmed: 7617034
Blood Cells Mol Dis. 2009 May-Jun;42(3):267-78
pubmed: 19233695
Am J Hum Genet. 1988 Mar;42(3):516-20
pubmed: 3348216
Science. 2001 Jul 20;293(5529):455-62
pubmed: 11423617
J Inflamm (Lond). 2015 Apr 24;12:34
pubmed: 25945076
PLoS One. 2013 Nov 04;8(11):e79566
pubmed: 24223971
J Vasc Res. 2007;44(4):253-63
pubmed: 17361089
Clin Exp Immunol. 2018 Mar;191(3):279-287
pubmed: 29277898
Cell Mol Immunol. 2021 Mar;18(3):770-772
pubmed: 32523113
Ann Thorac Med. 2012 Oct;7(4):226-32
pubmed: 23189100
Hematol Oncol Clin North Am. 2016 Apr;30(2):373-93
pubmed: 27040960
Am J Hum Genet. 1990 Dec;47(6):1013-9
pubmed: 1978555
Antioxid Redox Signal. 2013 Mar 20;18(9):1114-27
pubmed: 22938199
Ann Hematol. 2017 May;96(5):839-845
pubmed: 28197721
Oxid Med Cell Longev. 2021 Apr 29;2021:5529256
pubmed: 34007401
PLoS One. 2016 Apr 20;11(4):e0153462
pubmed: 27097228
J Epidemiol Community Health. 1987 Jun;41(2):89-93
pubmed: 3309118
Int J Environ Res Public Health. 2023 Feb 03;20(3):
pubmed: 36768075
Redox Biol. 2020 Jan;28:101363
pubmed: 31707353
J Pediatr. 1989 May;114(5):748-52
pubmed: 2715888
J Immunol. 2013 Jul 15;191(2):594-607
pubmed: 23752610
Hum Hered. 1982;32(1):46-8
pubmed: 6950922
J Inherit Metab Dis. 2008 Jun;31(3):412-7
pubmed: 18392752
J Clin Med. 2021 Nov 29;10(23):
pubmed: 34884340
Lancet. 2008 Jan 5;371(9606):64-74
pubmed: 18177777
Viruses. 2015 Dec 17;7(12):6689-706
pubmed: 26694452
Free Radic Res. 2013 Sep;47(9):699-709
pubmed: 23777333
PeerJ. 2020 Nov 03;8:e9971
pubmed: 33194371
J Gen Virol. 2008 Sep;89(Pt 9):2080-2089
pubmed: 18753216
Mod Rheumatol. 2014 Jul;24(4):612-7
pubmed: 24252052
Atherosclerosis. 2019 Mar;282:148-153
pubmed: 30731288
Free Radic Biol Med. 2011 May 15;50(10):1222-33
pubmed: 20946951
Nat Genet. 2011 Aug 14;43(9):902-7
pubmed: 21841778
J Med Genet. 1979 Dec;16(6):431-4
pubmed: 537014
Nature. 2003 Jul 31;424(6948):561-5
pubmed: 12891360
Medicine (Baltimore). 2016 Nov;95(44):e5254
pubmed: 27858887